The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1)

J. Chorostowska-Wynimko, J. Zaleska, M. Chabowski, A. Stepniewska, J. Zych, P. Rudzinski, R. Langfort, T. Orlowski, K. Roszkowski (Warsaw, Poland)

Source: Annual Congress 2006 - Biology and prognostic factors
Session: Biology and prognostic factors
Session type: Poster Discussion
Number: 2291
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Chorostowska-Wynimko, J. Zaleska, M. Chabowski, A. Stepniewska, J. Zych, P. Rudzinski, R. Langfort, T. Orlowski, K. Roszkowski (Warsaw, Poland). The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1). Eur Respir J 2006; 28: Suppl. 50, 2291

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007


Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008


Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Hypoxia inducible factor-1 alpha (HIF-1 alpha) expression was correlated with the survival in patients with small cell lung cancer (SCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Year: 2011


Serum levels of angiopoietin-1, angiopoietin-2 and their receptor- Tie-2 in patients with non small cell lung cancer during chemotherapy
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


The effect of SDF-1/CXCR4 on expression of VEGF and MMP-9 in small cell lung cancer
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012

Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008

Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


SiRNA mediated growth factor receptors inhibition in A549 cell model of lung cancer gene therapy: insulin-like growth factor-I receptor (IGF-R1) blockade produces changes that potentially induce anti-tumor immunity
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008


Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105)
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005

The growth of lung cancer cells is progressed by G-CSF and M-CSF due to activation of angiogenesis
Source: Eur Respir J 2003; 22: Suppl. 45, 224s
Year: 2003

A serum level of IGF-I, IGF-II and IGFBP-3 in patients with small cell lung cancer (SCLC) during chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 86s
Year: 2006